Results 261 to 270 of about 42,521 (302)
Some of the next articles are maybe not open access.
Journal of Clinical Endocrinology & Metabolism, 1999
Glucagon-like peptide 2 (GLP-2) is a 33 amino acid peptide-encoded carboxyterminal to the sequence of GLP-1 in the proglucagon gene. Both GLP-1 and GLP-2 are secreted from gut endocrine cells and promote nutrient absorption through distinct mechanisms of action.
openaire +3 more sources
Glucagon-like peptide 2 (GLP-2) is a 33 amino acid peptide-encoded carboxyterminal to the sequence of GLP-1 in the proglucagon gene. Both GLP-1 and GLP-2 are secreted from gut endocrine cells and promote nutrient absorption through distinct mechanisms of action.
openaire +3 more sources
Glucagon-like peptide-1 agonists
BMJ, 2012Cannot be recommended strictly for weight reduction until their benefits and risks are ...
openaire +2 more sources
Metabolic Messengers: glucagon-like peptide 1
Nature Metabolism, 2021Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin secretion, food intake and gut motility. GLP-1 forms the basis for a variety of current drugs for the treatment of type 2 diabetes and obesity, as well as new agents ...
Fiona M. Gribble, Frank Reimann
openaire +2 more sources
Glucagon and the Glucagon-Like Peptides
Pancreas, 1990Glucagon and the glucagon-like peptides are encoded within a larger precursor, proglucagon. The proglucagon gene is expressed in the pancreas, intestine, and brain, giving rise to a single proglucagon mRNA transcript that is identical in all tissues. Tissue-specific posttranslational processing of proglucagon accounts for the different molecular forms ...
openaire +2 more sources
Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry, 2012Patients with type 2 diabetes mellitus are at high risk for developing cardiovascular diseases. Traditional medicines for type 2 diabetes, such as sulfonylureas, pioglitazone, and insulin have glucose lowering effects; however, they also increase the frequency of hypoglycemia and/or body weight and thus may cancel out the benefits of glucose lowering ...
Tomoya, Mita, Hirotaka, Watada
openaire +2 more sources
Glucagon-like peptide-1 receptor
Current BiologyMichael Krashes discusses glucagon-like peptide-1 receptors, their physiological role in glucose metabolism and the mode of action of their agonists that are used to treat obesity and were later shown to promote weight loss.
openaire +2 more sources
Annals of the New York Academy of Sciences, 2006
Abstract: The glucagon‐like peptides, GLP‐1 and GLP‐2, are cosecreted by intestinal L cells in response to nutrient ingestion. These peptides exert multiple effects on the gastrointestinal tract and pancreas to regulate the digestion, absorption, and assimilation of ingested nutrients, as well as providing feedback signals to the brain to modulate ...
openaire +2 more sources
Abstract: The glucagon‐like peptides, GLP‐1 and GLP‐2, are cosecreted by intestinal L cells in response to nutrient ingestion. These peptides exert multiple effects on the gastrointestinal tract and pancreas to regulate the digestion, absorption, and assimilation of ingested nutrients, as well as providing feedback signals to the brain to modulate ...
openaire +2 more sources
Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2.
Best practice & research. Clinical endocrinology & metabolism, 2005The glucagon-like peptides (glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)) are released from enteroendocrine cells in response to nutrient ingestion. GLP-1 enhances glucose-stimulated insulin secretion and inhibits glucagon secretion, gastric emptying and feeding. GLP-1 also has proliferative, neogenic and antiapoptotic effects on
Laurie L, Baggio, Daniel J, Drucker
openaire +1 more source